Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Metabolic Cardiovascular Syndrome Clear all
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention

NCT03643705
View directory record Official record
Conditions
HIV/AIDS, Hypertension, Hyperlipidemias
Interventions
Multi-component intervention, General prevention education
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Multidisciplinary Inpatient Palliative Care Intervention

NCT00325611
View directory record Official record
Conditions
Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
Interventions
Multidisciplinary palliative care team met with patient
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2006 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Metformin Use in the Treatment of HIV

NCT00399360
View directory record Official record
Conditions
HIV Infections, Metabolic Syndrome X
Interventions
Metformin, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Sep 17, 2026, 5:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study on the Impact of Patient Navigators on the Health Education and Quality of Life in Formerly Incarcerated Patients

NCT02259634
View directory record Official record
Conditions
HIV/AIDS, Diabetes Mellitus, Hypertension, Substance Use
Interventions
Patient Navigation
Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional

The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV

NCT02214173
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
rice bran arabinoxylan compound (RBAC), Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 17, 2026, 5:03 AM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244
View directory record Official record
Conditions
HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions
r-metHuLeptin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome

NCT00857298
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Metabolic Syndrome, HIV Infections
Interventions
Dietary Intervention
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457
View directory record Official record
Conditions
HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions
Pioglitazone, Exercise training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

NCT00890747
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aggressive NK-cell Leukemia, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Malignancies, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV Infection, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Osteolytic Lesions of Multiple Myeloma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
sunitinib malate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2014 · Synced Sep 17, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

NCT05488431
View directory record Official record
Conditions
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
Interventions
Bempedoic acid, Placebo
Drug · Other
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
40 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

NCT00246376
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis
Interventions
Diet, Exercise, Niacin, Fenofibrate, Placebos
Behavioral · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

NCT00656851
View directory record Official record
Conditions
HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
Interventions
Pioglitazone, Exercise Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
28 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 17, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

NCT03960541
View directory record Official record
Conditions
HIV Infections, Dyslipidemias
Interventions
Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

NCT00000883
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 17, 2026, 5:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Assessment of Long-Haul Truck Drivers

NCT00381992
View directory record Official record
Conditions
Gonorrhea, Chlamydia Infections, Hepatitis B, Hepatitis C, Diabetes Mellitus, Hypertension, Obesity, HIV Infections, Hyperlipidemia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

NCT03207945
View directory record Official record
Conditions
Dyslipidemias, Cardiovascular Diseases, HIV Infections
Interventions
Alirocumab, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324
View directory record Official record
Conditions
Covid19
Interventions
AntiCov-220, AntiCov-220 (placebo)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
16 Years to 82 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 17, 2026, 5:03 AM EDT
Completed No phase listed Observational

Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology

NCT01089114
View directory record Official record
Conditions
HIV, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 17, 2026, 5:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Gender-Affirming Hormone Therapy Among Transgender Women

NCT04128488
View directory record Official record
Conditions
Transgender Women, HIV/AIDS, Cardiovascular Diseases, Metabolic Disease, Coagulopathy
Interventions
Abdominal MR Imaging, Cardiac MRI/MRS, Oral Glucose Tolerance Testing, Whole Body, Lumbar Spine, and Hip DEXA Imaging
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 99 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 17, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV

NCT05896852
View directory record Official record
Conditions
HIV-1-infection, Metabolic Syndrome
Interventions
physical activity
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 5:03 AM EDT